Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan;47(1):i.
doi: 10.1111/jcpt.13445. Epub 2021 Jul 12.

Retracted: Calcitonin Gene-Related Peptide (CGRP) Antagonists: A comprehensive review of safety, efficacy and prescribing information

Abubker Omaer  1   2   3 , Fahad M Aldosari  1   2   3 , Emily McGlamery  4 , Saad Alrashed  5 , Steven Wool  4 , Maryam T Fazel  2   3
Affiliations
Review

Retracted: Calcitonin Gene-Related Peptide (CGRP) Antagonists: A comprehensive review of safety, efficacy and prescribing information

Abubker Omaer et al. J Clin Pharm Ther. 2022 Jan.

Retraction in

Abstract

What is known and objectives: Migraine is a disabling disorder that affects individuals of all ages. To date, there are multiple limitations to using guidelines-recommended treatments and preventive therapies. The goal of this review was to provide a comprehensive clinical review of the safety, efficacy and prescribing information of the emerging calcitonin gene-related peptide (CGRP) antagonists. Agents in this new pharmacologic class were approved by the US Food and Drug Administration (FDA) for the treatment of acute migraine attack pain and the management of episodic and chronic migraine.

Methods: A total of 12 randomized, placebo-controlled clinical trials were identified and included in the review utilizing databases such as clinicaltrial.gov, PubMed and EMBASE. The trials collectively evaluated six CGRP antagonists starting from the orally administered CGRPs such as rimegepant and ubrogepant, to the quarterly IV administered CGRP such as eptinezumab, and the monthly/quarterly subcutaneously administered agents such as erenumab, fremanezumab and galcanezumab.

Results and discussion: All agents displayed significant efficacy compared with placebo, measured by reduction in mean monthly migraine days (MMD). In addition, CGRP antagonists displayed a great tolerability profile with few adverse effects. These medications were neither associated with any cardiovascular-related adverse effects, nor do they currently have specific contraindications to pre-existing cardiovascular conditions. This can present a safe alternative to a wide range of patients who cannot be appropriately treated with first-line treatments such as triptans. No treatment-related death was reported in any of the clinical trials outlined and discussed.

What is new and conclusion: Calcitonin gene-related peptide antagonists are safe and efficacious medications both in treating acute migraine headache pain and the management of episodic and chronic migraine. Head-to-head comparative studies with current guideline-recommended treatments are needed. However, CGRP antagonists are promising agents that present an alternative solution for patients living with migraine.

Keywords: CGRP; acute; calcitonin gene-related peptide antagonists; chronic; episodic; management; migraines; prevention.

PubMed Disclaimer

References

REFERENCES

    1. Alexander L. (the BF. History of Headache). https://headacheaustralia.org.au/what-is-headache/history-of-headache/. Published 2020. Accessed July 29, 2020.
    1. Pearce JM. Historical aspects of migraine. J Neurol Neurosurg Psychiatry. 1986;49(10):1097-1103. https://doi.org/10.1136/jnnp.49.10.1097
    1. Viana M, Khaliq F, Zecca C, et al. Poor patient awareness and frequent misdiagnosis of migraine: findings from a large transcontinental cohort. Eur J Neurol. 2020;27(3):536-541. https://doi.org/10.1111/ene.14098
    1. Mayans L, Walling A. Acute migraine headache: treatment strategies. Am Fam Physician. 2018;97(4):243-251.
    1. Silberstein SD, Edlund W. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the quality standards subcommittee of the American academy of neurology. Neurology. 2000;55(6):754-762. https://doi.org/10.1212/WNL.55.6.754

LinkOut - more resources